Press

• In the upcoming month of November, the Spanish Association of Biocompanies (AseBio) will celebrate its 25th anniversary.
• The milestone will shape AseBio's work throughout 2024 through various actions and activities aimed at highlighting its transformative role in biotechnology in Spain.
• AseBio has been a key player in the journey taken over these 25 years by biotechnology in Spain, positioning itself as a strategic agent in the face of challenges and future prospects.

• In the General Assembly of AseBio, new vice-presidents have also been elected: Carlos Buesa, CEO of Oryzon (First Vice-presidency); Cristina Nadal, Policy Executive Director of MSD Spain (Second Vice-presidency); and Adriana Casillas, CEO and co-founder of Tebrio (Third Vice-presidency).
• The General Assembly of AseBio has also chosen eight board members.
• "It is an honor to be part of the AseBio presidency alongside three individuals and companies that are leaders in our Spanish biotechnological sector and globally," states the new president of AseBio.

• The list, comprised of 268 drugs, is an important tool to support the EU's efforts to ensure the security of the supply chain and prevent shortages of critical medications.
• Over the last 40 years, biotechnology has shaped the landscape of medicine, as evidenced by the fact that 69% of drugs in development are a result of biotechnological advancements.
• Biotechnology plays a key role in achieving what the European Commission has termed the "European Health Union," ensuring patients' access to medications.

The purpose behind our request for the creation of the High Commissioner is to strengthen Spain's commitment to deep technologies at a critical moment for Europe's strategic autonomy.

• The biotech sector provides cross-cutting solutions ranging from the diagnosis, research, and treatment of infectious diseases to the development of innovative preventive and therapeutic strategies, through the development of vaccines, the study of the microbiome, or new uses of existing antibiotics.
• The map reveals that 43 AseBio partners are taking direct actions aimed at combating antibiotic resistance through various capabilities.
• Most of these biotech organizations focus on human health, but a quarter of them focus their activities on animal health or do so in a cross-cutting manner.

• Beyond the direct impact of biotechnology on human health and the planet, investment in science and biotechnology has a direct relationship with the competitiveness, sustainability, and economic resilience of countries.
• Biotechnological innovations will determine the well-being of future generations, but for this to happen and for Spain to fully harness its potential, there needs to be a political and social will that provides the industry with measures and resources to ensure its full development.
• Spain needs a clear regulatory framework and support for the biotechnological industry with long-term investments, support that specifically addresses the needs of biotech companies, and measures to boost research talent.

• The President of the Generalitat de Catalunya, Pere Aragonès i Garcia, and the General Manager of Amgen and member of the Board of Directors of AseBio and the Board of Trustees of Biocat, Fina Lladós, officially close the fair.
•  Over 2,100 attendees and more than 220 exhibitors gathered over the course of the three-day congress.
• BIOSPAIN has evolved into a platform for fostering the next generation of startups, with over 5,000 one-to-one meetings and more than 30 startup presentations to investors.

• Ensuring food security and mitigating the impacts of climate change will not be possible without innovation in agriculture.
• Through food waste and the insect industry, proteins are being produced in a more sustainable manner.
• Biotechnology enables the transformation of certain types of waste into raw materials for industry, avoiding their disposal in landfills and reducing the footprint of processes and products.

• The sector has radically transformed the discovery of new drugs and therapeutic solutions.
• Worldwide, there are over 300 approved medications for approximately 250 indications and a thousand molecules in various stages of research.
• Biotechnological development is opening new horizons in the field of mental health.